May 15, 2018
Antengene Co., Ltd. announced on May 15, 2018 that Dr. Yijun Yang and Dr. Bo Shan joined Antengene as Vice President. Dr. Yijun will be responsible for corporation affairs, clinical trial and biostatistics; Dr. Bo Shan will be responsible for drug discovery and pharmaceutical manufacturing.
According to Dr. Jay Mei, Chief Executive Officer of Antengene, “Dr. Yang, with extensive experience in biostatistics and clinical pharmacology, will contribute significantly to the company’s clinical project development and external cooperation; Dr. Shan has rich practical experience in early drug development and GMP plant construction and we believe that he will display more abilities in related fields.”
Yijun Yang holds a PhD in Biostatistics from the Boston University and a PhD in Clinical Epidemiology of the Dutch Academy of Health Sciences. Dr. Yang has nearly twenty-year experience in biostatistics and clinical pharmacology, and has worked at several multi-national pharmaceutical companies, including Vertex Pharmaceuticals, Acceleron Pharmaceuticals and Wyeth Pharmaceuticals, where he was responsible for design and management of clinical stage programs, biostatistics method selection, clinical trial data analysis and evaluation, and new drug commercialization. Before joining Antengene, he has been in charge of the biostatistics and clinical pharmacology at Synageva, MediVector and Ziopharm Pharceumaticals. Under his lead, these companies have successfully built and developed biostatistics teams with optimized clinical trial program and improved efficiency.
Bo Shan, Doctor of Pharmaceutical Chemistry, Aston University, UK, is a member of China National “Thousand Talent Program” and in charge of National "Thirteenth Five-Year Science and Technology Major Project".
Prior to joining Antengene, Dr. Shan was the Vice President of Ascletis Bioscience Limited, where he was responsible for CMC development and manufacturing and has successfully accomplished the commercialization of one Category I new drug and the Phase III clinical trial of another; Meanwhile, he led the team in the workshop construction, structural design, equipment purchase, process validation and trial production of Ascletis’ Shaoxing site. Dr. Shan also has significant experience working in early-stage drug development. Dr. Shan has worked as scientist in pharmaceutical chemical development at Maybridge Ltd and GE Healthcare, where he developed eight new drugs, ten generic drugs, and one innovative diagnostic reagent, among which the drug for the treatment of ovarian cancer and breast cancer has already been commercialized in the United States and the European Union and a series of candidate new drugs are currently at different clinical stages.
Antengene Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to meet unmet medical needs in Asia. Antengene aims to provide the most advanced and first-in-class anti-cancer drug treatments for patients in China and rest of Asia. On April 13, 2017, Celgene Corporation (Nasdaq:CELG), a global leading innovative biopharmaceutical company became a long-term strategic partner and obtained an equity position in Antengene. Antengene currently has several investigational programs at Phase 2/3 stage. Antengene’s lead pipeline asset ATG-008, a dual mTORC1/2 inhibitor, is currently in multi-regional clinical trials (MRCT) for the treatment of hepatocellular carcinoma (HCC) patients in Asian countries/regions including mainland China, Taiwan, and South Korea. For more information, please visit www.antengene.com.